Funded by the Dick Vitale Gala in memory of Eddie Livingston
Anti-GD2 monoclonal antibodies are now standard of care for patients with high-risk neuroblastoma, but there is little information on their biodistribution and tumor targeting in patients. We are developing a third generation anti-GD2 MoAb humanized 3F8 (hu3F8) for therapy of neuroblastoma. This proposed study will use a small dose of radioactive hu3F8 to determine its distribution and targeting using PET imaging which can provide sophisticated and quantitative data. This information will be critical in refining current dosing regimens for hu3F8 and improve the design of future clinical studies. Moreover, if specific tumor targeting can be demonstrated, as study of radioactive hu3F8 for therapy of patients with poor-prognosis neuroblastoma will be initiated.
